Maintenance of these ground state cells is possible using a combination of basic fibroblast growth factor and human leukemia inhibitory factor together with dual inhibition of glycogen synthase kinase 3 beta, and mitogen‐activated protein kinase kinase (MEK). The gene discussed is MAP2K7; the disease is leukemia.